Company news
Armata Pharmaceuticals, Inc. news in 2026
Armata Pharmaceuticals, Inc.'s news releases, calls and decks from 2026, newest first.
Armata Pharmaceuticals Receives $3.7 Million in Additional Non-Dilutive Funding from U.S. Department of War to Support Advancement of AP-SA02 Phase 3 Development
September 23, 2026
Armata Pharmaceuticals to Present Data at ISSSI 2026 Showing Defined Genetic Diversity in AP-SA02 May Enhance Killing of Certain Staphylococcus aureus Clinical Isolates
September 21, 2026
Armata Pharmaceuticals Receives U.S. FDA Breakthrough Therapy Designation for AP-SA02
September 14, 2026
Armata Pharmaceuticals to Participate in the H.C. Wainwright 28th Annual Global Investment Conference
September 10, 2026
Armata Pharmaceuticals Announces New Publication That Advances Understanding of Phage Biology to Support Development of Next-Generation Antibacterials
September 3, 2026
Armata Pharmaceuticals Announces Financial Results for the Second Quarter 2026 and Provides a Corporate Update
August 12, 2026
Armata Pharmaceuticals Achieves Key Progress Across Clinical, Regulatory and Manufacturing Activities Supporting Planned Phase 3 Initiation of AP-SA02
July 20, 2026
Armata Pharmaceuticals Receives Agreement from FDA on Initial Pediatric Study Plan for AP-SA02 for the Treatment of Complicated Staphylococcus aureus Bacteremia
July 13, 2026
Armata Pharmaceuticals Receives $2.5 Million of Additional Non-Dilutive Award Funding from the U.S. Department of Defense to Support AP-SA02
June 23, 2026
Armata Pharmaceuticals Announces First Quarter 2026 Results and Provides Corporate Update
May 13, 2026
Armata Pharmaceuticals Secures FDA Fast Track Designation for AP-SA02
May 7, 2026
Armata Pharmaceuticals Announces Structural Biology Publication in "Communications Biology"
May 4, 2026
Armata Pharmaceuticals Announces Appointment of Biopharmaceutical Commercial Executive Daniel B. Gilmer, Ph.D. to its Board of Directors
April 27, 2026
Armata Pharmaceuticals Announces Fourth Quarter and Full-Year 2025 Financial Results
March 25, 2026
Armata Pharmaceuticals Delays Announcement of Fourth Quarter and Full-Year 2025 Results and Provides Corporate Update
March 19, 2026
Armata Pharmaceuticals Receives FDA Qualified Infectious Disease Product (QIDP) Designation for AP-SA02
February 23, 2026
Armata Pharmaceuticals Announces End-of-Phase 2 Meeting with FDA and Plans to Advance AP-SA02 to a Phase 3 Superiority Study in Complicated Staphylococcus aureus Bacteremia
January 14, 2026
Correction: Armata Pharmaceuticals, Inc.
January 13, 2026
Decks in 2026
- Investor Presentation (September 2026)
Investor deck · 52 slides · Sep 14, 2026